---
title: "Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IVVD Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291536796.md"
description: "Invivyd, Inc. (Nasdaq: IVVD) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On July 1, 2026, the company granted options to purchase 493,000 shares to 14 newly hired non-executive employees as material inducements for joining the firm. The options carry an exercise price of $0.8544 per share, vest over four years, and have a 10-year term."
datetime: "2026-07-02T03:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291536796.md)
  - [en](https://longbridge.com/en/news/291536796.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291536796.md)
---

# Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IVVD Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8544, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

**About Invivyd**

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

**Contacts:**

**Media Relations**  
(781) 208-0160  
media@invivyd.com

**Investor Relations**  
(781) 208-1747  
investors@invivyd.com

### Related Stocks

- [IVVD.US](https://longbridge.com/en/quote/IVVD.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Wilco 63 units begin separate trading of shares and warrants Aug. 10](https://longbridge.com/en/news/295025929.md)
- [Photocure grants board share options with NOK 58.9 strike price](https://longbridge.com/en/news/295256931.md)
- [McKesson director Bradley E. Lerman disposes of 301 common shares worth $268.789,83](https://longbridge.com/en/news/295566730.md)
- [Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market](https://longbridge.com/en/news/295551199.md)
- [UBS Group raises Klöckner voting rights stake to 5.43% from 3.39%](https://longbridge.com/en/news/295564172.md)